Drugs / Recombinant Human Adenovirus 5 Injection
last change Oct 2025 re-read 3 minutes ago

Recombinant Human Adenovirus 5 Injection

Developed for
cervical cancer
Investigated by
Fujian Cancer Hospital · Zhangzhou Municipal Hospital of Fujian Province

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06455046 Oct 2023 → Oct 2025 cervical cancer Fujian Cancer Hospital Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant Human Adenovirus 5 Injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455046 ↗
Route Other “local injection of Human Adenovirus 5 Injection” NCT06455046 ↗